GDPMD and Market Surveillance Inspections for Devices in Pakistan

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Devices circulating in Pakistan are subject to Good Distribution Practice for Medical Devices (GDPMD). Provincial health departments administer sales and distribution activities, while DRAP conducts on-site inspections of storage facilities. The inspection focus concentrates on three items: temperature control, hygiene conditions and storage capacity. Market patrols, for their part, cover distribution qualifications, label compliance and product condition. For imported brands there is a structural discomfort in this arrangement: the warehouse is their weak point, because the licence-holding party usually does not directly control the warehouse. The company that owns the certificate and the company that owns the shelf space are often different legal entities, operating under different management systems, and the regulator inspects the second on the strength of the first. An imported brand therefore inherits every weakness of its partner’s storage operation. Managing distribution compliance in Pakistan means managing an operation you do not own, which requires contractual leverage, periodic verification and a willingness to act on what the verification finds. The practical risk is asymmetric as well: distribution failures accumulate quietly, in the form of drifted refrigerators and incomplete ledgers, long before any single incident makes them visible to the regulator.

2. Legal basis

The relevant provisions are set out below. They cover the inspection power over facilities, the limited exemption route, and two label requirements that market patrols examine most directly. The distribution practice standard itself sits alongside the rules as the operational benchmark against which storage and distribution performance is judged.

Institutional licence and on-site inspectionMedical Devices Rules, 2017Rule 15(1)
On-site inspection exemptionSame instrumentRule 15(2)
Label: local representative informationSame instrumentRule 24(b)
Label consistent with approved versionSame instrumentRule 14(6)
Distribution and traceability practiceGDPMDpractical estimate and industry compilation

3. Expert insights

Insight one: the on-site inspection examines whether goods can be stored properly, not whether a licence exists. The three focus items — temperature control, hygiene conditions and storage capacity — are in essence a verification that the storage conditions match the storage requirements stated on the product labelling and instructions for use. A licence only opens the door to the warehouse; what the inspectors evaluate inside is physical reality. Cold chain products are the most likely to get stuck here, because a cold room that works on paper but drifts in practice fails the test precisely at the parameter that matters most. Companies with ambient products should not relax either: humidity, cleanliness and shelving capacity are assessed with the same seriousness, and a warehouse that mixes product categories must satisfy the strictest applicable requirement among them.

Insight two: the exemption in Rule 15(2) targets the inspection of manufacturing sites and does not exempt warehousing. We highlight this point specifically: the exemption available through reference-country approvals points to inspection of the manufacturing site; the storage and distribution conditions after import into Pakistan remain within the scope of regulation. The confusion arises because both inspections involve the word “site”, but they examine different premises in different countries under different standards. A manufacturer that holds approvals from a recognised reference jurisdiction should not conclude that its Pakistani warehouse inherits the exemption. Goods that left a well-inspected factory can still be ruined in an uninspected storeroom, and the regulator’s concern follows the product, not the factory gate. Reading the exemption narrowly is therefore the safe interpretation, and any broader reading should be confirmed with the authority before it is relied upon in a submission.

Insight three: the label is the most immediately visible check item in market patrols. Rule 24(b) requires local representative information on the label, and Rule 14(6) requires the label to be consistent with the approved version. These two requirements hold simultaneously, which means the label must carry the Pakistani information and must not deviate from the approved version of the country of origin or the reference country — this needs to be coordinated at the design stage, not patched afterwards. A label revised late in the process tends to satisfy one requirement and violate the other, because the local additions push the artwork away from the approved master. Early artwork planning with both rules on the table avoids that collision entirely, and it costs nothing except an earlier decision on where the Pakistani text sits on the layout.

4. Practical recommendations

GRZAN’s approach at the distribution stage is the three-check routine: check the warehouse, examining temperature and humidity recording equipment together with its historical data; check the ledgers, confirming that inward and outward records and flow records are traceable; and check the labels, comparing the physical goods accompanying shipments item by item against the approved artwork. These three checks are performed at least once every year, and they must be repeated in full whenever the warehouse operator changes, because a change of operator resets every assumption about equipment, personnel and records. The checks are deliberately simple, since their purpose is not to replace the authority’s inspection but to find problems before the authority does. A finding recorded in an internal check leads to a corrective action on the company’s own schedule; the same finding recorded by an inspector leads to a corrective action on the regulator’s schedule, with the certificate implications that follow from it. The order of the three checks is also deliberate: the warehouse check verifies conditions, the ledger check verifies traceability, and the label check verifies conformity, so together they cover the three subjects that patrols and inspections respectively target.

5. Verification checklist

  • □ The warehouse has passed the DRAP on-site inspection (temperature control / hygiene conditions / storage capacity)
  • □ Temperature and humidity recording equipment is in use and historical data is retained
  • □ Inward and outward ledgers and flow records are traceable to batch level
  • □ Shipping labels carry the local representative name and address (Rule 24(b))
  • □ Labels have been checked against the approved version of the country of origin or reference country (Rule 14(6))

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Pakistan. Our team prepares dossiers to DRAP expectations, manages eCTD-format submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail